-
-
-
-
-
-
-
William Blair Reiterates Outperform Rating on Silence Therapeutics (SLN)
-
-
-
-
-
-
-
Silence Therapeutics (SLN) PT Lowered to $30 at Jefferies
-
-
-
-
-
-
-
Silence Therapeutics (SLN) Presents Late-Breaking Phase 2 Zerlasiran Data at 2024 American Heart Association Annual Meeting
-
-
-
-
-
-
-
H.C. Wainwright Reiterates Buy Rating on Silence Therapeutics (SLN)
-
-
418,855 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

